3 completed, 1 recruiting, 1 unknown. 3 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow AZD3759: new trials by email Literature Review of AZD3759 trials Research Report on AZD3759
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zorifertinib With Osimertinib for NSCLC With Meningeal Progression Zorifertinib and Osimertinib Combination Therapy - Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment | Phase 1 | Recruiting | Alpha Biopharma (Jiangsu) Co., Ltd. | 42 | 2026-01-31 | 2026-06-22 |
| First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases AZD3759, Erlotinib, Gefitinib - Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 / Phase 3 | Completed | Alpha Biopharma (Jiangsu) Co., Ltd. | 492 | 2018-10-29 | 2025-09-10 |
| Phase II Umbrella Study Directed by Next Generation Sequencing Avitinib Maleate, Afatinib, Crizotinib - Carcinoma, Non-Small-Cell Lung | Phase 2 | Unknown | Guangdong Association of Clinical Trials | 400 | 2018-07-09 | 2022-12-06 |
| Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 AZD3759 - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | LYZZ Alpha Holding Ltd | 15 | 2017-10-30 | 2022-11-25 |
| Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer AZD3759, AZD9291 - EGFR Mutation Positive Advanced Non Small Cell Lung Cancer | Phase 1 | Completed | AstraZeneca | 108 | 2014-11-05 | 2021-01-05 |
Carcinoma, Non-Small-Cell Lung (4) · Brain Neoplasms (2) · Lung Neoplasms (2) · Meningeal Carcinomatosis (2) · Neoplasms (1) · Respiratory Tract Diseases (1)
Alpha Biopharma (Jiangsu) Co., Ltd. (2) · AstraZeneca (1) · Guangdong Association of Clinical Trials (1) · LYZZ Alpha Holding Ltd (1)
China (4) · South Korea (2) · Taiwan (2) · Australia (1) · Singapore (1) · United States (1)
Jie Wang, M.D. (1) · Myung-Ju Ahn, M.D. (1) · Pamela Yang, M.D. PhD (1) · Qing Zhou, M.D. (1) · Yi-Long Wu (1) · Yilong Wu, M.D. (1) · Yilong Wu, Professor (1)
PMID 11937001, PMID 15844174, PMID 15897941, PMID 16983123, PMID 18172267, PMID 20627894, PMID 25336382, PMID 25923549, PMID 26334749, PMID 27435396, PMID 27751847, PMID 27959700, PMID 28673332, PMID 28881917, PMID 29056570, PMID 29151359, PMID 30512189, PMID 31027690, PMID 31809241, PMID 31887431, PMID 35659479, PMID 37488286, PMID 38666433, PMID 39389055, PMID 6699671